One of the most consistent findings across omega-3 clinical research is the effect of EPA and DHA supplementation on triglyceride levels, a key cardiovascular risk marker.
Randomized controlled trials have demonstrated that higher daily intakes of combined EPA and DHA significantly reduce triglyceride concentrations, particularly in individuals with elevated baseline levels. Read the triglyceride dose‑response trial (PMC)
Dose-Response Relationship
Clinical research indicates a clear dose-response relationship, meaning larger daily omega-3 doses generally produce greater triglyceride reductions, particularly in high-risk populations.
Meta-analysis data also suggest that omega-3 intake between approximately 2–3 grams per day may produce measurable cardiovascular risk-marker improvements in certain individuals. (American Heart Association Journals)
Mechanisms of Lipid Metabolism Regulation
Omega-3 fatty acids influence triglyceride levels through:
-
Reduced hepatic triglyceride synthesis
-
Increased fatty acid oxidation
-
Enhanced clearance of circulating triglyceride particles
-
Regulation of lipid metabolism pathways (PubMed)
These mechanisms explain why triglyceride reduction is one of the most consistently observed clinical outcomes of omega-3 supplementation.
Key Takeaway
Across multiple randomized trials and dose-response analyses, higher intake of EPA and DHA omega-3 fatty acids consistently demonstrates triglyceride-lowering effects, supporting their role in cardiovascular risk-management nutrition strategies.